Adults with moderate to severe DPN pain were titrated to tapentadol ER 100-250 mg bid during a 3-week open-label period ; patients with 1-point reduction in pain intensity ( 11-point numerical rating scale ) at end of titration were randomized to receive placebo or tapentadol ER ( optimal dose from titration ) for 12 weeks ( double-blind , fixed-dose maintenance phase ) .